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Metabolic Syndrome and Incident Diabetes
Current state of the evidence
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OBJECTIVE— Our objective was to perform a quantitative review of prospective studies
examining the association between the metabolic syndrome and incident diabetes.
RESEARCH DESIGN AND METHODS— Using the title terms “diabetes” and “meta-
bolic syndrome” in PubMed, we searched for articles published since 1998.
RESULTS— Based on the results from 16 cohorts, we performed a meta-analysis of estimates
of relative risk (RR) and incident diabetes. The random-effects summary RRs were 5.17 (95% CI
3.99–6.69) for the 1999 World Health Organization definition (ten cohorts); 4.45 (2.41–8.22)
for the 1999 European Group for the Study of Insulin Resistance definition (four cohorts); 3.53
(2.84–4.39) for the 2001 National Cholesterol Education Program definition (thirteen cohorts);
5.12 (3.26–8.05) for the 2005 American Heart Association/National Heart, Lung, and Blood
Institute definition (five cohorts); and 4.42 (3.30–5.92) for the 2005 International Diabetes
Federation definition (nine cohorts). The fixed-effects summary RR for the 2004 National Heart,
Lung, and Blood Institute/American Heart Association definition was 5.16 (4.43–6.00) (six
cohorts). Higher number of abnormal components was strongly related to incident diabetes.
Compared with participants without an abnormality, estimates of RR for those with four or more
abnormal components ranged from 10.88 to 24.4. Limited evidence suggests fasting glucose
alone may be as good as metabolic syndrome for diabetes prediction.
CONCLUSIONS— The metabolic syndrome, however defined, has a stronger association
with incident diabetes than that previously demonstrated for coronary heart disease. Its clinical
value for diabetes prediction remains uncertain.
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S ince major organizations such as theWor ld Hea l th Organ iza t ion(WHO), the European Group for
the Study of Insulin Resistance (EGIR),
and the National Cholesterol Education
Program (NCEP) released definitions of
the metabolic syndrome, it has received a
great deal of attention in the scientific lit-
erature. Much has been learned about the
many facets of the syndrome, including
its prevalence, incidence, and risks of
leading to the development other condi-
tions such as cardiovascular disease and
diabetes.
Because of the controversy that has
enveloped the concept of the metabolic
syndrome, a thorough understanding of
the association between the syndrome
and diabetes—one of the main risks for
people with the metabolic syndrome—is
critical to furthering the debate about the
syndrome’s scientific relevance. At the
time of a previous quantitative review,
only a limited number of prospective
studies of the metabolic syndrome and in-
cident diabetes were available (1). Since
that review, additional definitions of the
syndrome have joined the previous ones,
and the results of more prospective stud-
ies have been published. Therefore, the
main objective of this study was to pro-
vide an updated quantitative review of the
estimates of relative risk (RR) from pro-
spective studies of the association be-
tween the metabolic syndrome and
incident diabetes. In addition, we sum-
marize other pertinent findings of these
prospective studies. We also try to place
the results into clinical context by com-
paring metabolic syndrome assessment
with other, potentially simpler methods
of assessing risk of incident diabetes.
RESEARCH DESIGN AND
METHODS—A literature search using
the title terms “metabolic syndrome” and
“diabetes” was conducted in PubMed. We
limited the search to articles that were
written in English. Because the WHO was
the first to release its definition, in 1998,
we started our search for articles pub-
lished that year and continued through
April 2008. We reviewed titles and ab-
stracts of the search results and retrieved
promising articles. In addition, we aug-
mented our search with reviews of the ref-
erence lists of retrieved articles.
The focus of this article is the pro-
spective association between the meta-
bolic syndrome and incident diabetes in
studies that are more or less population
based. Therefore, we did not include
studies that recruited participants with
specific conditions such as cardiovascular
disease. To be included in the analyses,
articles had to include estimates of RR and
CIs based on one of the major definitions
of the metabolic syndrome (2–7). Articles
that presented estimates of RR only in
graphical form were not included in the
quantitative analyses because of the diffi-
culty in accurately deriving the estimate
of RR and its CI. When multiple estimates
were available for a particular cohort, only
the estimate that most thoroughly ad-
justed for covariates or that presented es-
timates for men and women combined
was selected. Some studies did not have
all criteria required to define the meta-
bolic syndrome according to established
criteria, and, consequently, researchers
modified definitions of the metabolic syn-
drome. For example, several studies used
BMI instead of waist circumference (8–
10). Two reviews relating metabolic syn-
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drome to risk for vascular events noted
similar RR estimates for studies based on
use of BMI, waist circumference, or waist-
to-hip ratio (1,11). Furthermore, one co-
hort did not have concentrations of HDL
cholesterol (12,13). We included these
studies in our summary. In addition, the
WHO definition technically requires that
participants undergo an oral glucose tol-
erance test (OGTT), have insulin resis-
tance based on a gold-standard technique
(specifically, the hyperinsulinemic-
euglycemic clamp), and undergo a mea-
surement of microalbuminuria. Most
studies were unable to satisfy these crite-
ria. Therefore, we included studies that
did not conduct an OGTT, used a surro-
gate measure of insulin resistance (such as
fasting concentration of insulin or ho-
meostasis model assessment of insulin re-
sistance [HOMA-IR]), and did not
measure microalbuminuria. We ab-
stracted the following data elements: lead
author’s name, year of publication, study
name and location, sample size, fol-
low-up time, sex composition and age of
subjects (mean, median, or range), exclu-
sion criteria, metabolic syndrome defini-
tion (including any changes), definition
of diabetes, number of incident events,
estimate of RR (odds ratio [OR], RR, or
hazard ratio), 95% CI, and variables used
to adjust estimates of RR.
SEs for the estimates of RR were esti-
mated from the CIs. For each study, a
weight was calculated as the inverse of the
variance (1/SE2). Heterogeneity among
studies was assessed using the Q statistic
(14). If no heterogeneity was present (P of
Q statistic0.10), fixed-effects estimates
of RR were calculated according to the
inverse variance method (15). If hetero-
geneity was present (P of Q statistic
0.10), random-effects estimates of RR
were calculated using the approach of Der
Simonian and Laird (14). The influence of
single studies on the summary estimates
was examined graphically by checking
how the elimination of each study af-
fected the resulting summary estimate of
RR (16). Evidence for publication bias
was assessed by examining funnel plots
and assessing funnel plot asymmetry
(17). Analyses were conducted using
Stata 9.2.
RESULTS—For our quantitative anal-
yses, we included articles that are based
on 16 cohorts (supplemental table avail-
able in an online appendix at http://
dx.doi.org/10.2337/dc08-0423) (8 –
10,12,13,18 –32). These 16 cohorts
included over 2,604 incident events
among 42,419 participants, depending
on which of the multiple publications of
the same cohort were included in the
counts. Three cohorts included only men,
whereas the other 13 included both men
and women. Follow-up times ranged
from 2.3 to 20 years. Two studies were
not included because results were pre-
sented only in graphical form (33) or con-
fidence limits were not provided (34).
Ten cohorts yielded estimates of RR
for the association of the metabolic syn-
drome and incident diabetes defined us-
ing the WHO 1999 definition, and the
random-effects summary RR was 5.17
(95% CI 3.99–6.69) (Fig. 1). Four co-
horts yielded estimates of RR for the EGIR
1999 definition, and the random-effects
summary RR was 4.45 (2.41–8.22). Thir-
teen cohorts provided an estimate of RR
for the NCEP 2001 definition, and the
random-effects summary RR was 3.53
(2.84–4.39). Six cohorts reported esti-
mates of RR for the National Heart, Lung,
and Blood Institute/American Heart As-
sociation (NHLBI/AHA) 2004 defini-
tion, and the fixed-effects summary RR
was 5.16 (4.43– 6.00). Five cohorts re-
ported estimated RRs for the AHA/
NHLBI 2005 definit ion, and the
random-effects summary RR was 5.12
(3.26 – 8.05). Nine cohorts produced
estimates of RRs for the International
Diabetes Federation (IDF) 2005 defini-
tion, and the random-effects summary
RR was 4.42 (3.30 –5.92). Funnel plot
asymmetry was detected only for the
analysis involving the NCEP 2001 defi-
nition (Egger’s test: P  0.028).
Comparing the summary RRs for the
different definitions shown above is to
some degree problematic because of dif-
ferences in study populations and analytic
approaches. Thus, a fairer comparison is
between results from sets of studies that
examined the same definitions and calcu-
lated estimated RRs in the same manner.
Five studies compared the WHO 1999
and NCEP 2001 defin i t ions
(12,18,23,29,32). The random-effects
summary RR was 4.40 (95% CI 2.87–
6.75) for WHO 1999 and the fixed-effects
summary RR was 3.12 (2.68–3.64) for
NCEP 2001. Three studies compared the
WHO 1999, NCEP 2001, and IDF 2005
definitions (23,29,32). The random-
effects summary RR was 5.73 (3.04 –
10.79) for the WHO 1999 definition, and
the fixed-effects summary RRs were 3.50
(2.91–4.22) for the NCEP 2001 defini-
tion and 3.51 (2.83–4.36) for the IDF
2005 definition. Five studies compared
the NCEP 2001 and IDF 2005 definitions.
The random-effects and fixed-effects
summary RRs were 4.10 (3.13–5.39) and
3 .72 (2 .97– 4 .67 ) , r e spec t i v e l y
(23,27,29,30,32). Five studies compared
the AHA/NHLBI 2005 and IDF 2005 def-
initions, yielding random-effects sum-
mary RRs of 5.12 (3.26–8.05) and 5.00
(2.84 – 8.78), respectively (13,25–
27,30). Four studies of the EGIR 1999
and IDF 2005 definitions produced ran-
dom-effects summary RRs of 4.45 (2.41–
8.22) and 4.33 (2.34–8.01), respectively
(13,26,29,31). Two studies included the
NCEP 2001, AHA/NHLBI 2005, and IDF
2005 definitions (27,29). Summary RRs
were 6.16 (2.67–14.20) (random-
effects), 4.51 (3.22–6.30) (fixed-effects),
and 4.15 (2.88–5.96) (fixed-effects), re-
spectively. Two studies included the
WHO 1999, EGIR 1999, and NCEP 2001
definitions (12,29). The fixed-effects
summary RRs were 4.09 (3.25–5.14),
2.78 (2.15–3.58), and 3.13 (2.46–3.99),
respectively. Three studies compared the
NCEP 2001, NHLBI/AHA 2004, and IDF
2005 definitions (23,27,32). The fixed-
effects summary RRs were 3.95 (3.18–
4.90), 4.44 (3.57–5.52), and 3.77 (3.03–
4.70), respectively. Four studies provided
results for the WHO 1999 and IDF 2005
definitions (23,29,31,32). The random-
effects summary RRs were 6.19 (3.85–
9.95) and 3.95 (3.01–5.19), respectively.
Finally, three studies produced information
about the WHO 1999 and EGIR 1999 def-
initions (12,29,31). The random-effects
summary RRs were 4.47 (2.79–7.18) and
3.47 (1.81–6.63), respectively.
Sensitivity, specificity, positive
predictive value, negative predictive
value, and receiver operating
characteristic curve
Estimates of sensitivity and specificity
were ava i l ab le fo r t en cohor t s
(10,20,21,25,27,29,31–33,35), and esti-
mates of positive and negative predictive
values were available for six cohorts
(25,27,29,31,32,35). Sensitivity ranged
from 0.224 to 0.722, and specificity
ranged from 0.613 to 0.939 (Table 1).
Positive predictive values ranged from
0.078 to 0.36 and negative predictive val-
ues range from 0.90 to 0.983. Receiver
operating characteristic curves were gen-
erated for six cohorts with the area under
the receiver operating characteristic curve
(aROC), ranging from 0.68 to 0.85
(10,20,23,26,32,35). For studies com-
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paring existing definitions, differences
among the aROCs were small and gener-
ally nonsignificant (20,23,26,35).
Number of metabolic syndrome
components
Several studies examined the risk associ-
ated with increasing number of compo-
nents of the metabolic syndrome (Table
2). In these studies, subjects with zero ab-
normalities formed the reference group.
Three studies based their criteria on those
of the NCEP 2001 definition. The esti-
mated RRs for participants in the West of
Scotland Coronary Prevention Study (8)
were 7.26 (95% CI: 2.25–23.40) for those
with three abnormalities and 24.4 (7.53–
79.60) for those with four or more abnor-
malities. Estimated RRs for participants
with three abnormalities and four or more
abnormalities were 4.56 (2.48–8.78) and
10.88 (5.77–20.50), respectively, in the
British Regional Heart Study (10). In the
Framingham Offspring Study, the esti-
mated RR for participants with three or
more abnormalities was 23.83 5.80 –
98.01) among men and 29.69 (9.10 –
96.85) among women (22). Furthermore,
at least two other studies using criteria not
based on one of the major definitions also
showed substantially elevated estimated
RRs associated with three and four or
more of abnormalities (28,36).
Figure 1—Estimates of RR from prospective studies examining the associations between the metabolic syndrome and incident diabetes.
Metabolic syndrome and diabetes
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CONCLUSIONS— The prospective
studies show that the metabolic syn-
drome, regardless of how it is defined, is a
significant predictor of incident diabetes
in many different populations, including
Native Americans, U.S. Hispanics, Mexi-
cans, Turks, Iranians, Mauritians, Chi-
nese, Europeans, and those of European
descent. Although considerable heteroge-
neity existed among these studies, the av-
erage estimated summary RR of 3.5–5.2
for incident diabetes with any metabolic
syndrome criteria is greater than the asso-
ciation of metabolic syndrome with car-
diovascular events (1.5 to 2.0) (1,11).
These data confirm that the metabolic
syndrome is significantly more strongly
associated with risk for incident diabetes,
likely because some of its components (in
particular fasting glucose and waist cir-
cumference) are more strongly associated
with diabetes risk.
The heterogeneity among studies em-
anates from at least two sources: the ori-
gins of the study population and the
approach in analyzing the study data. For
example, with the NCEP 2001 definition,
Native Americans cohorts produced a
fixed-effects summary RR of 1.98 (95% CI
1.69–2.32) (18,19), Asian and Mauritius
cohorts produced a fixed-effects sum-
mary RR of 3 .53 (2 .96 – 4.20)
(9,12,27,29,32), and North American
Table 1—Sensitivity, specificity, positive predictive value, negative predictive value, and aROC reported from prospective studies reporting on
the association between the metabolic syndrome and incident diabetes
Reference
number Year Metabolic syndrome definition Sensitivity Specificity PPV NPV aROC
33 2002 Modified WHO 1998, WHR 0.91 0.67 0.80
Modified WHO 1998, WC 94 cm 0.57 0.83
NCEP 2001, WC 102 cm 0.41 0.90
NCEP 2001, WC 94 cm 0.49 0.84
20 2003 NCEP 2001 0.528 0.849 0.308 0.934 0.776
Modified WHO 1999 0.428 0.872 0.304 0.921 0.762
21 2004 NCEP 2001 (SAHS) 0.662 0.722
NCEP 2001 (MCDS) 0.624 0.613
35 2005 NCEP 2001 0.50 0.82 0.36 0.90 0.75
NCEP 2001, FPG 100–125 mg/dl 0.64 0.74 0.32 0.91 0.75
NCEP 2001, augmented 0.81 0.61 0.29 0.94 0.78
23 2005 NCEP 2001 0.69
WHO 1999 0.68
IDF 2005 0.68
10 2005 Number of abnormalities over 10 years 0.626 0.747 0.72
Number of abnormalities over 20 years 0.539 0.757 0.70
25 2007 IDF 2005 0.703 0.746
AHA/NHLBI 2005 0.611 0.831
Modified WHO 1999 0.549 0.866
26 2007 AHA/NHLBI 2005 0.82–0.85
IDF 2005 0.82–0.85
EGIR 1999 0.78–0.84
27 2007 NCEP 2001 0.258 0.939 0.246 0.943
NHLBI/AHA 2004 0.342 0.919 0.244 0.948
AHA/NHLBI 2005 0.419 0.875 0.205 0.951
IDF 2005 0.317 0.902 0.199 0.945
29 2007 Modified WHO 1999 0.421 0.882 0.268 0.937
NCEP 2001 0.389 0.850 0.208 0.932
EGIR 1999 0.224 0.921 0.224 0.921
IDF 2005 0.240 0.907 0.209 0.921
IDF 2005 with WHO obesity 0.464 0.838 0.226 0.939
NCEP 2001 with WHO obesity 0.553 0.793 0.214 0.946
IDF 2005 with reduced WC 0.498 0.792 0.196 0.939
31 2008 WHO 1999 0.564 0.829 0.115 0.980
NCEP 2004 0.622 0.764 0.099 0.981
EGIR 1999 0.464 0.859 0.116 0.976
IDF 2005 0.649 0.713 0.082 0.981
32 2008 Modified WHO 1999 0.5479 0.9081 0.1973 0.9799
NCEP 2001 0.6075 0.7327 0.0863 0.9782 0.72
IDF 2005 0.7219 0.6468 0.0779 0.9824
NHLBI/AHA 2004 0.7043 0.6999 0.0889 0.9827 0.74
ADA, American Diabetes Association; FPG, fasting plasma glucose; MCDS, Mexico City Diabetes Study; NPV, negative predictive value; PPV, positive predictive
value; SAHS, San Antonio Heart Study; WC, waist circumference; WHR, waist-to-hip ratio.
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and European studies produced a ran-
dom-effects summary RR of 4.13 (3.16–
5.40) (8,10,20,21,23,30). The variables
used to adjust estimated RRs varied con-
siderably among studies, with some ad-
justing for nothing, others for multiple
factors, and others potentially overadjust-
ing with use of, for example, OGTTs.
Although a variety of diabetes risk
prediction models exist, some not requir-
ing any laboratory measures, three direct
comparisons of the predictive ability of
the metabolic syndrome and a single dia-
betes risk score, the Diabetes Risk Score,
have been conducted (21,29,31). This
prediction model includes age, sex, eth-
nicity, fasting glucose, systolic blood
pressure, HDL cholesterol, BMI, and fam-
ily history of diabetes (37). Thus, four
components of the metabolic syndrome
as per the NCEP 2001 definition and sub-
sequent revisions (with BMI in lieu of
waist circumference) are represented in
continuous form in this model. Both in
the San Antonio Heart Study and the
Mexico City Diabetes Study, the sensitiv-
ity of the Diabetes Risk Score was signifi-
cantly larger than that of metabolic
syndrome diagnosis at a given specificity
(21). In a study conducted in Mauritius,
Cameron et al. concluded that the Diabe-
tes Predicting Model provided somewhat
better prediction than the metabolic syn-
drome (29). Using data of the AusDiab
study, Cameron et al. reached a similar
conclusion (31).
Furthermore, the concept of risk
scores using routinely available or easily
collectable data has emerged as an appeal-
ing tool for predicting both undiagnosed
prevalent diabetes and the risk for future
incident diabetes. The Finnish Diabetes
Risk Score (FINDRISC)—using categori-
cal variables for age, BMI, waist circum-
ference, history of antihypertensive drugs
or high blood glucose, physical activity,
and daily consumption of fruit, berries,
and vegetables—achieved an aROC be-
tween 0.85 and 0.87 for 10-year incident
diabetes (38), exceeding the aROC re-
ported in all the metabolic syndrome
studies reporting these data (Table 2).
However, results from the AusDiab study
showed that a modified version of
FINDRISC (score10) had a worse pos-
itive predictive value and specificity at a
comparable sensitivity than the metabolic
syndrome using the NCEP 2001 and IDF
2005 definitions (31). Similarly, the re-
cent German Diabetes Risk Score (com-
prising age, height, waist circumference,
history of hypertension, physical activity,
smoking, and dietary factors) has re-
ported an aROC for incident diabetes of
between 0.82 and 0.84 (39).
Of the components of the metabolic
syndrome, impaired fasting glucose is
generally thought to be the strongest pre-
dictor of diabetes (8,12,13,22,27,29,
31,40). Like that of Cameron et al., most
studies reported that concentrations of
fasting glucose provided similar or, as in
the AusDiab study, better prediction of
diabetes than metabolic syndrome diag-
nosis (31). However, Lorenzo et al. (25)
showed that the metabolic syndrome pro-
vided additional prediction beyond that
provided by impaired fasting glucose
alone in the San Antonio Heart Study.
Little research has been conducted
examining the predictive ability of the
various combinations of metabolic syn-
drome components in definitions such as
the NCEP 2001, NHLBI/AHA 2004, and
AHA/NHLBI 2005. One possible reason
for this is that many studies have not had
sufficient incident events of diabetes to
evaluate the many combinations. For ex-
ample, the NCEP 2001 definition and the
two subsequent updates yield 16 combi-
nations of three or more cardiometabolic
abnormalities. Using data from the Fra-
mingham Offspring Study, Wilson et al.
(22) did examine a number of combina-
tions of the five NHLBI/AHA 2004 com-
ponents and concluded that the RRs of
combinations of three abnormalities were
not larger than combinations of two fac-
tors or, indeed, elevated fasting glucose
alone.
Another issue that has received little
attention is whether the metabolic syn-
drome represents more than the sum of its
parts. Cameron et al. (29) found that only
the WHO 1999 definition—not the
NCEP 2001, EGIR 1999, or IDF 2005
definitions—significantly added to the
prediction of incident diabetes in models
that included the individual components
of the metabolic syndrome. Using data
from the West of Scotland Coronary Pre-
vention Study, Sattar et al. (8) concluded
that the metabolic syndrome was not a
significant predictor of incident diabetes
once its components were accounted for.
A number of researchers have exam-
ined the effect of changing aspects of the
definition of the metabolic syndrome on
the predictive ability of the syndrome for
diabetes. Lowering waist circumference
or glucose thresholds generally increased
the prevalence of the metabolic syndrome
and the sensitivity but at the expense of
specificity (8,32,33,35).
Some of the most extensive efforts at
improving the predictive ability of the
metabolic syndrome, starting with the
NCEP 2001 definition, were conducted
by Hanley et al. (23) using data from the
Insulin Resistance Atherosclerosis Study.
To some degree, the numerous changes
that the authors tested affected the prev-
alence of the metabolic syndrome, the
ORs for incident diabetes, and the popu-
lation-attributable risk. The lowest
aROCs of 0.66 were observed for defini-
tions that required fasting plasma glucose
or elevated waist circumference as man-
datory components. The highest aROC of
0.72 was observed for a definition that
included the insulin sensitivity index as a
sixth component.
A couple of investigations also com-
pared the predictive ability of the meta-
bolic syndrome with that of individual
components of the metabolic syndrome
or ones closely related to it. In the San
Antonio Heart Study, Lorenzo et al. (20)
reported that the aROC for NCEP 2001
was similar to that for the 2-h glucose
Table 2—Estimates of OR, RR, or hazard ratio (HR) using zero abnormalities as the reference
category from prospective studies reporting on the association between the metabolic syn-
drome and incident diabetes
Reference
number Year
Number of
criteria OR/RR/HR
95% Lower
limit
95% Upper
limit
36 2002 3 9.37 2.22 39.59
4 33.67 7.93 142.96
8 2003 3 7.26 2.25 23.4
4 24.4 7.53 79.6
22 2005 (Men) 3 23.83 5.80 98.01
22 2005 (Women) 3 29.69 9.10 96.85
10 2005 3 4.56 2.48 8.78
4 10.88 5.77 20.50
28 2007 3 7.05
4 13.39 4.26 42.08
Metabolic syndrome and diabetes
1902 DIABETES CARE, VOLUME 31, NUMBER 9, SEPTEMBER 2008
value. Hanley et al. (23) examined the
predictive ability of impaired glucose tol-
erance, quantitative insulin sensitivity
check index, insulin sensitivity, the ratio
of concentrations of triglycerides to HDL
cholesterol, hypertriglyceridemic waist,
and concentrations of C-reactive protein
compared with NCEP 2001, WHO 1999,
and IDF 2005 definitions of metabolic
syndrome. The prevalence of these condi-
tions ranged from a low of 18.4% for the
hypertriglyceridemic waist to a high of
69.6% for a concentration of C-reactive
protein1 mg/l. A concentration of C-re-
active protein3 mg/l yielded the lowest
OR for incident diabetes (1.83 [95% CI:
1.23–2.74]), aROC (0.60), and popula-
tion-attributable risk (19.4%), whereas
impaired glucose tolerance yielded the
highest OR (5.42 [3.60–8.17]), aROC
(0.72), and population-attributable risk
(58.47%).
Our study illustrates that the meta-
bolic syndrome is a fairly strong predictor
of incident diabetes in many populations
and that it predicts diabetes more strongly
than it predicts coronary heart disease
events. However, whether the metabolic
syndrome was ever intended to be more
strongly predictive of diabetes than car-
diovascular disease is not entirely clear.
Additional comparisons of the metabolic
syndrome to simple, readily available
non–laboratory-based questionnaires are
needed because questionnaires appear
better placed as initial screening tools to
identify high-risk individuals, whose sub-
sequent evaluation would incorporate the
results from blood tests. Moreover, on the
balance of current but limited evidence, it
appears that the metabolic syndrome may
not add to the prediction of incident dia-
betes beyond its components, in particu-
lar impaired fasting glucose, although
more data are needed to confirm this. The
most successful attempts to improve the
predictive ability of the metabolic syn-
drome appear to have revolved around
creating more of a continuous scale from
its components, emphasizing loss of
power from a dichotomous use of data.
Current evidence casts substantial doubt
on the clinical value of diagnosing the
metabolic syndrome to identify those at
elevated risk for diabetes.
References
1. Ford ES: Risks for all-cause mortality, car-
diovascular disease, and diabetes associ-
ated with the metabolic syndrome: a
summary of the evidence. Diabetes Care
28:1769–1778, 2005
2. World Health Organization: Definition, di-
agnosis, and classification of diabetes mellitus
and its complications. Report of a WHO con-
sultation. Part I: diagnosis and classification
of diabetes mellitus. Geneva, World Health
Org., 1999 (WHO/NCO/NCS/99.2)
3. Balkau B, Charles MA: Comment on the
provisional report from the WHO consul-
tation. European Group for the Study of
Insulin Resistance (EGIR). Diabet Med 16:
442–443, 1999
4. Executive Summary of The Third Report
of The National Cholesterol Education
Program (NCEP) Expert Panel on Detec-
tion, Evaluation, And Treatment of High
Blood Cholesterol In Adults (Adult Treat-
ment Panel III). JAMA 285:2486–2497,
2001
5. Grundy SM, Brewer HB, Jr, Cleeman JI,
Smith SC, Jr, Lenfant C: Definition of met-
abolic syndrome: Report of the National
Heart, Lung, and Blood Institute/Ameri-
can Heart Association conference on
scientific issues related to definition.
Circulation 109:433–438, 2004
6. Alberti KG, Zimmet P, Shaw J: The meta-
bolic syndrome–a new worldwide defini-
tion. Lancet 366:1059–1062, 2005
7. Grundy SM, Cleeman JI, Daniels SR, Do-
nato KA, Eckel RH, Franklin BA, Gordon
DJ, Krauss RM, Savage PJ, Smith SC, Jr,
Spertus JA, Costa F: Diagnosis and man-
agement of the metabolic syndrome: an
American Heart Association/National
Heart, Lung, and Blood Institute Scientific
Statement. Circulation 112:2735–2752,
2005
8. Sattar N, Gaw A, Scherbakova O, Ford I,
O’Reilly DS, Haffner SM, Isles C, Macfar-
lane PW, Packard CJ, Cobbe SM, Shep-
herd J: Metabolic syndrome with and
without C-reactive protein as a predictor
of coronary heart disease and diabetes in
the West of Scotland Coronary Prevention
Study. Circulation 108:414–419, 2003
9. Lim HS, Lip GY, Beevers DG, Blann AD:
Factors predicting the development of
metabolic syndrome and type II diabetes
against a background of hypertension.
Eur J Clin Invest 35:324–329, 2005
10. Wannamethee SG, Shaper AG, Lennon L,
Morris RW: Metabolic syndrome vs Fra-
mingham Risk Score for prediction of cor-
onary heart disease, stroke, and type 2
diabetes mellitus. Arch Intern Med 165:
2644–2650, 2005
11. Gami AS, Witt BJ, Howard DE, Erwin PJ,
GamiLA,SomersVK,MontoriVM:Metabolic
syndrome and risk of incident cardiovascular
events and death: a systematic review and
meta-analysisof longitudinalstudies. JAmColl
Cardiol 49:403–414, 2007
12. Wang JJ, Hu G, Miettinen ME, Tuom-
ilehto J: The metabolic syndrome and
incident diabetes: assessment of four sug-
gested definitions of the metabolic syn-
drome in a Chinese population with high
post-prandial glucose. Horm Metab Res
36:708–715, 2004
13. Wang JJ, Li HB, Kinnunen L, Hu G, Jarvi-
nen TM, Miettinen ME, Yuan S, Tuom-
ilehto J: How well does the metabolic
syndrome defined by five definitions
predict incident diabetes and incident
coronary heart disease in a Chinese
population? Atherosclerosis 192:161–168,
2007
14. DerSimonian R, Laird N: Meta-analysis in
clinical trials. Control Clin Trials 7:177–
188, 1986
15. Greenland S: Quantitative methods in the
review of epidemiologic literature. Epide-
miol Rev 9:1–30:1–30, 1987
16. Tobias A: Assessing the influence of a sin-
gle study in meta-analysis. Stata Tech Bull
47:15–17, 1999
17. Egger M, Davey SG, Schneider M, Minder C:
Bias in meta-analysis detected by a simple,
graphical test. BMJ 315:629–634, 1997
18. Hanson RL, Imperatore G, Bennett PH,
Knowler WC: Components of the “meta-
bolic syndrome” and incidence of type 2
diabetes. Diabetes 51:3120–3127, 2002
19. Resnick HE, Jones K, Ruotolo G, Jain AK,
Henderson J, Lu W, Howard BV: Insulin
resistance, the metabolic syndrome, and
risk of incident cardiovascular disease in
nondiabetic American Indians: the Strong
Heart Study. Diabetes Care 26:861–867,
2003
20. Lorenzo C, Okoloise M, Williams K, Stern
MP, Haffner SM: The metabolic syndrome
as predictor of type 2 diabetes: the San
Antonio heart study. Diabetes Care 26:
3153–3159, 2003
21. Stern MP, Williams K, Gonzalez-Villal-
pando C, Hunt KJ, Haffner SM: Does the
metabolic syndrome improve identifica-
tion of individuals at risk of type 2 diabetes
and/or cardiovascular disease? Diabetes
Care 27:2676–2681, 2004
22. Wilson PW, D’Agostino RB, Parise H, Sul-
livan L, Meigs JB: Metabolic syndrome as
a precursor of cardiovascular disease and
type 2 diabetes mellitus. Circulation 112:
3066–3072, 2005
23. Hanley AJ, Karter AJ, Williams K, Festa A,
D’Agostino RB, Jr, Wagenknecht LE,
Haffner SM: Prediction of type 2 diabetes
mellitus with alternative definitions of the
metabolic syndrome: the Insulin Resis-
tance Atherosclerosis Study. Circulation
112:3713–3721, 2005
24. Meigs JB, Wilson PW, Fox CS, Vasan RS,
Nathan DM, Sullivan LM, D’Agostino RB:
Body mass index, metabolic syndrome,
and risk of type 2 diabetes or cardiovas-
cular disease. J Clin Endocrinol Metab 91:
2906–2912, 2006
25. Lorenzo C, Williams K, Hunt KJ,
Haffner SM: The National Cholesterol
Education Program-Adult Treatment
Panel III, International Diabetes Feder-
ation, and World Health Organization
definitions of the metabolic syndrome
Ford, Li, and Sattar
DIABETES CARE, VOLUME 31, NUMBER 9, SEPTEMBER 2008 1903
as predictors of incident cardiovascular
disease and diabetes. Diabetes Care 30:
8 –13, 2007
26. Meigs JB, Rutter MK, Sullivan LM, Fox
CS, D’Agostino RB, Sr, Wilson PW: Im-
pact of insulin resistance on risk of type 2
diabetes and cardiovascular disease in
people with metabolic syndrome. Diabe-
tes Care 30:1219–1225, 2007
27. Cheung BM, Wat NM, Man YB, Tam S,
Thomas GN, Leung GM, Cheng CH, Woo
J, Janus ED, Lau CP, Lam TH, Lam KS:
Development of diabetes in Chinese with
the metabolic syndrome: a 6-year pro-
spective study. Diabetes Care 30:1430-
1436, 2007
28. Elwood PC, Pickering JE, Fehily AM: Milk
and dairy consumption, diabetes and the
metabolic syndrome: the Caerphilly pro-
spective study. J Epidemiol Community
Health 61:695–698, 2007
29. Cameron AJ, Zimmet PZ, Soderberg S, Al-
berti KG, Sicree R, Tuomilehto J, Chitson
P, Shaw JE: The metabolic syndrome as a
predictor of incident diabetes mellitus in
Mauritius. Diabet Med 24:1460–1469,
2007
30. Mannucci E, Monami M, Cresci B, Pala L,
Bardini G, Petracca MG, Dicembrini I,
Pasqua A, Buiatti E, Rotella CM: National
Cholesterol Education Program and In-
ternational Diabetes Federation defini-
tions of metabolic syndrome in the
prediction of diabetes. Results from the
FIrenze-Bagno A Ripoli study. Diabetes
Obes Metab 10:430–435, 2008
31. Cameron AJ, Magliano DJ, Zimmet PZ,
Welborn TA, Colagiuri S, Tonkin AM,
Shaw JE: The metabolic syndrome as a
tool for predicting future diabetes: the
AusDiab study. J Intern Med Epub ahead
of print, 2008
32. Hadaegh F, Ghasemi A, Padyab M, To-
hidi M, Azizi F: The metabolic syn-
drome and incident diabetes: Assess-
ment of alternative definitions of the met-
abolic syndrome in an Iranian urban pop-
ulation. Diabetes Res Clin Pract 80:328–
334, 2008
33. Laaksonen DE, Lakka HM, Niskanen LK,
Kaplan GA, Salonen JT, Lakka TA: Meta-
bolic syndrome and development of dia-
betes mellitus: application and validation
of recently suggested definitions of the
metabolic syndrome in a prospective co-
hort study. Am J Epidemiol 156:1070-
1077, 2002
34. Onat A, Hergenc G, Keles I, Dogan Y,
Turkmen S, Sansoy V: Sex difference in
development of diabetes and cardiovas-
cular disease on the way from obesity and
metabolic syndrome. Metabolism 54:
800–808, 2005
35. Schmidt MI, Duncan BB, Bang H, Pankow
JS, Ballantyne CM, Golden SH, Folsom
AR, Chambless LE: Identifying individu-
als at high risk for diabetes: The Athero-
sclerosis Risk in Communities study.
Diabetes Care 28:2013–2018, 2005
36. Klein BE, Klein R, Lee KE: Components of
the metabolic syndrome and risk of car-
diovascular disease and diabetes in Beaver
Dam. Diabetes Care 25:1790–1794, 2002
37. Stern MP, Williams K, Haffner SM: Iden-
tification of persons at high risk for type 2
diabetes mellitus: do we need the oral glu-
cose tolerance test? Ann Intern Med 136:
575–581, 2002
38. Lindstrom J, Tuomilehto J: The diabetes
risk score: a practical tool to predict type 2
diabetes risk. Diabetes Care 26:725–731,
2003
39. Schulze MB, Hoffmann K, Boeing H,
Linseisen J, Rohrmann S, Mohlig M,
Pfeiffer AF, Spranger J, Thamer C, Haring
HU, Fritsche A, Joost HG: An accurate
risk score based on anthropometric, di-
etary, and lifestyle factors to predict the
development of type 2 diabetes. Diabetes
Care 30:510–515, 2007
40. Macchia A, Levantesi G, Borrelli G,
Franzosi MG, Maggioni AP, Marfisi R,
Scarano M, Tavazzi L, Tognoni G, Vala-
gussa F, Marchioli R: A clinically prac-
ticable diagnostic score for metabolic
syndrome improves its predictivity of
diabetes mellitus: the Gruppo Italiano
per lo Studio della Sopravvivenza
nell’Infarto miocardico (GISSI)-Preven-
zione scoring. Am Heart J 151:754,
2006
Metabolic syndrome and diabetes
1904 DIABETES CARE, VOLUME 31, NUMBER 9, SEPTEMBER 2008
